Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in ...

Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic ...

Cognition Therapeutics (CGTX) reported preclinical data this week at the Association for Research in Vision and Ophthalmology showing the ...

Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial ...

Age-related macular degeneration begins with weakening of retinal pigment epithelium cells (RPEs ... delivery of compounds to modulate microglia function and alleviate the progression of age ...

Pilatus Biosciences, a biotechnology company developing immunometabolic therapies for cancer, today announced a preclinical publication in Cancer Discovery detailing the mechanism and therapeutic ...

In ocular diseases, for example, differentiated photoreceptor cells might replace lost photoreceptors, restoring visual function ... newly differentiated retinal pigment epithelial cells, derived ...

Age-related macular degeneration begins with weakening of retinal pigment epithelium cells (RPEs), a layer of cells ... of EV-based delivery of compounds to modulate microglia function and alleviate ...

NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, 1023 ...